ETs, including estrogen receptor modulators, aromatase inhibitors, and gonadotropin-releasing hormone agonists, are often prescribed as an adjunct to other cancer treatments to reduce cancer cell growth, metastasis, and recurrence, and generally have relatively lower side effects than other cancer treatment options, such as chemotherapy. Here, ESR1 is linked to cancer.